Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Company leaders to be joined by prostate cancer patient advocates, physicians and survivors

iCAD , Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announced that the executive management team, including President and CEO Ken Ferry, will ring the closing bell at the NASDAQ MarketSite in New York City’s Times Square on September 2, 2010 at 4:00 PM ET in recognition of Prostate Cancer Awareness month. Faina Shtern, MD, President and CEO of Admetech, a nonprofit organization dedicated to ending the prostate cancer crisis by supporting the development of accurate diagnostic tools for early detection and minimally-invasive treatment, will also be in attendance along with other physicians and prostate cancer survivors.

“I am honored to ring the NASDAQ closing bell, and pleased to be provided the opportunity to raise awareness about prostate cancer,” said Ken Ferry, President and CEO of iCAD. “Early detection is an important first-line defense towards the goal of successful cancer treatment, and iCAD is proud to provide advanced image analysis solutions that help clinicians make more accurate diagnosis in conjunction with available screening tools.”

One in six men will be affected by prostate cancer over the course of their lifetime, and MRI plays an important role in the accurate diagnosis and treatment decisions facing prostate cancer patients. VividLook , iCAD ’s Prostate MRI advanced image analysis solution, helps radiologists determine malignant from benign tissues and pinpoint tumor location and size. Additionally, VividLook provides enhanced diagnostic information by utilizing data from all available time points, creating colorized image maps based on signal changes defined by tumor physiology. With advanced diagnostic imaging tools, physicians can more accurately determine the extent of the prostate cancer, minimize a patient’s exposure to unnecessary and painful biopsies and provide more detailed information for men who choose active surveillance versus surgical or therapeutic treatment.

Source: iCAD , Inc.